Acetylsalicylic Acid

證據等級: L5

預測適應症: 10 個

Acetylsalicylic Acid: From Platelet Inhibition and Analgesia to Migraine with Brainstem Aura

One-Sentence Summary

Acetylsalicylic acid (aspirin, DB00945) is a widely-used analgesic, antipyretic, and antiplatelet agent whose efficacy in pain, fever, and cardiovascular thromboprevention has been established for decades. The TxGNN model predicts it may be effective for Migraine with Brainstem Aura, with 0 registered clinical trials and 19 publications currently supporting this research direction. Evidence is primarily derived from observational studies, a systematic review, and an evidence-based clinical guideline, placing it at the L3 level—sufficient to frame a research hypothesis, but not yet to guide clinical practice.

Quick Overview

Item	Content
Original Indication	No Singapore regulatory data available (drug not registered in this market)
Predicted New Indication	Migraine with Brainstem Aura
TxGNN Prediction Score	99.94%
Evidence Level	L3 (Observational studies / Systematic review)
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Research Question (Hold pending prospective evidence)

Why is This Prediction Reasonable?

Migraine with brainstem aura (formerly basilar-type migraine) involves cortical spreading depression (CSD) that propagates into brainstem structures, triggering the trigeminovascular pathway and releasing vasoactive neuropeptides. A growing body of evidence points to platelet activation as a facilitator of CSD: activated platelets release serotonin (5-HT), which can sensitise trigeminal nerve endings, while platelet-derived thromboxane A2 (TXA2) promotes cranial vasoconstriction that may contribute to aura initiation.

Acetylsalicylic acid irreversibly inhibits COX-1, thereby blocking TXA2 synthesis in platelets without fully suppressing prostacyclin (PGI2) production in vascular endothelium. The resulting shift in the TXA2/PGI2 balance favours vasodilation and reduced platelet aggregation—both potentially beneficial in a disorder characterised by episodic microvascular dysfunction. A retrospective cohort study (PMID 25729594, n=203) found that low-dose ASA was used prophylactically in migraine with aura patients with clinically meaningful results, and a 2025 systematic review (PMID 39989443) specifically evaluated antithrombotic drugs as migraine preventives.

Additionally, migraine with brainstem aura carries a higher risk of ischaemic stroke than migraine without aura, meaning ASA's antiplatelet and anti-inflammatory effects could offer dual benefit. The mechanistic plausibility is therefore genuine, though the evidence base remains insufficient for routine clinical use without dedicated prospective trials.

Clinical Trial Evidence

Currently no clinical trials specifically evaluating acetylsalicylic acid for migraine with brainstem aura are registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
25729594	2014	Retrospective Cohort	Current Health Sciences Journal	Evaluated ASA as prophylaxis in 203 migraine-with-aura patients (ICHD-II criteria); 95 subjects (46.8%) received low-dose ASA for ≥4 months, providing preliminary tolerability and efficacy data
39989443	2025	Systematic Review	Headache	Systematic review exploring available evidence on antithrombotic drugs (including ASA) as migraine preventive medication; directly addresses the repurposing question
25600718	2015	Evidence-based Guideline	Headache	American Headache Society updated evidence assessment of migraine pharmacotherapies; supports ASA/aspirin-caffeine combinations for acute mild-to-moderate migraine
10448545	1999	RCT	Cephalalgia	Double-blind, randomised, multicenter trial (n=278): IV lysine acetylsalicylate (= 1 g ASA) vs subcutaneous sumatriptan vs placebo in acute migraine with or without aura
34384631	2021	Review	Revue Neurologique	Comprehensive review of migraine with aura, covering cortical spreading depression (CSD) as the aura mechanism and diagnostic criteria under ICHD-III
30291554	2018	Review	Current Pain and Headache Reports	Reviews pathophysiological, epidemiological, and clinical differences between migraine with and without aura; highlights higher stroke risk in aura subtype relevant to ASA's antiplatelet benefit
15891416	2005	Review	Current Opinion in Neurology	Elucidates relationship between patent foramen ovale, cryptogenic stroke, and migraine with aura; supports antiplatelet rationale for this subtype
16103551	2005	Observational	Heart	Clopidogrel (another antiplatelet agent) reduced migraine with aura after transcatheter closure of atrial shunts, indirectly supporting the antiplatelet mechanism in this condition
35006660	2022	Review/Guideline	FP Essentials	AHA/ASA stroke primary prevention guideline; addresses the elevated stroke risk in migraine with aura and the role of antiplatelet therapy
33525313	2021	Review	Neurology International	Reviews ubrogepant and migraine treatment options; explicitly notes aspirin and aspirin-caffeine combinations as standard acute treatment for mild-to-moderate migraine

Singapore Market Information

Acetylsalicylic acid has no registered products in Singapore under the current dataset. No authorization records are available.

Note: This finding is atypical for a widely available over-the-counter analgesic and antiplatelet agent. It is recommended to verify this status directly with the Health Sciences Authority (HSA) Singapore database, as registration data for non-prescription products or products registered under other frameworks may not be captured in this dataset.

Safety Considerations

Please refer to the package insert for safety information. No Singapore-specific safety data (TFDA-equivalent warnings, contraindications, or drug interactions) were available in this evidence pack.

Based on general pharmacological knowledge:

Key precautions relevant to this indication: ASA is contraindicated in patients under 16 years of age with viral illness (Reye's syndrome risk) and in patients with active peptic ulcer disease or known hypersensitivity to NSAIDs.
Caution is warranted in patients with asthma (aspirin-exacerbated respiratory disease) and in combination with other anticoagulants/antiplatelets (increased bleeding risk).
The dose used for migraine prophylaxis (typically 100–300 mg/day) differs from analgesic doses; the benefit-risk profile at prophylactic doses in migraine with brainstem aura specifically has not been characterised in a prospective trial.

Conclusion and Next Steps

Decision: Research Question (Hold)

Rationale: While the mechanistic hypothesis is plausible—platelet-mediated TXA2 inhibition addressing a component of CSD/trigeminovascular activation—the available evidence consists of a single retrospective cohort, one systematic review of antithrombotics in migraine, and indirect support from guidelines and observational data. No prospective clinical trial has directly tested ASA specifically in migraine with brainstem aura, and the drug has no Singapore regulatory footprint to leverage.

To proceed, the following is needed:

Prospective clinical trial: A randomised, placebo-controlled trial evaluating low-dose ASA (e.g., 100 mg/day) as prophylaxis specifically in patients with confirmed migraine with brainstem aura (ICHD-III criteria).
Mechanism of action data: Formal DrugBank MOA retrieval and linkage to CSD/trigeminovascular biology to strengthen the biological rationale.
Safety data package: Download and parse the full prescribing information (package insert) to characterise contraindications, warnings, and DDIs relevant to a headache disorder population (including co-administration with triptans).
Singapore regulatory pathway assessment: Confirm actual HSA registration status and determine whether an indication extension submission would be required or whether off-label prophylactic use is practised.
Subgroup differentiation: Clarify whether evidence from migraine with aura (general) is transferable to the brainstem aura subtype, which carries distinct clinical and stroke-risk implications.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.